Clinical Advances in Dermatology: Pathophysiology, Diagnosis and Treatment

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: 20 August 2024 | Viewed by 1279

Special Issue Editors


E-Mail Website
Guest Editor
Dermatology Department, Hospital Universitario San Cecilio, 18016 Granada, Spain
Interests: psoriasis; atopic dermatitis; urticaria; biosimilars
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Dermatology and Venereology, Hospital Universitario Reina Sofia, 14004 Córdoba, Spain
Interests: psoriasis; atopic dermatitis; urticaria; biosimilars pediatric dermatology; trichology

Special Issue Information

Dear Colleagues,

The eruption of great therapeutic advances in our field, with the incorporation of biological drugs and molecules such as JAK (Janus Kinase) inhibitors, has advanced the knowledge of diagnosis thanks to new scales and results reported by patients that are being included in studies, clinical trials and randomized trials. New therapeutic targets and a better understanding of the pathophysiology of some immune-mediated diseases, such as psoriasis, atopic dermatitis, vitiligo, hidradenitis, urticaria or alopecia areata, have also emerged. In this issue, we will delve into the advances that are taking place in the different fields of clinical dermatology regarding these pathologies.

Dr. Ricardo Ruíz-Villaverde
Dr. Manuel Galán-Gutiérrez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriasis
  • atopic dermatitis
  • laser therapy
  • urticaria
  • alopecia areata
  • treatment
  • biological treatment
  • JAK (Janus Kinase) inhibitors

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 277 KiB  
Article
Changes in Serum IL-12 Levels following the Administration of H1-Antihistamines in Patients with Chronic Spontaneous Urticaria
by Corina Daniela Ene, Milena Tocut, Mircea Tampa, Simona Roxana Georgescu, Clara Matei, Iulia Maria Teodora Leulescu, Ilinca Nicolae and Cosmin Ene
J. Pers. Med. 2024, 14(3), 295; https://doi.org/10.3390/jpm14030295 - 10 Mar 2024
Viewed by 997
Abstract
Introduction. Research regarding the role of the IL-12 cytokine family in modulating immune and inflammatory responses is continuously evolving. In this study, the contribution of the p35 and p40 subunits as monomers (noted as IL-12p35 and IL-12p40) and heterodimers (noted as IL-12p70 or [...] Read more.
Introduction. Research regarding the role of the IL-12 cytokine family in modulating immune and inflammatory responses is continuously evolving. In this study, the contribution of the p35 and p40 subunits as monomers (noted as IL-12p35 and IL-12p40) and heterodimers (noted as IL-12p70 or IL-12p35/p40) was analysed in the pathophysiology and progression of chronic spontaneous urticaria (CSU). Materials and methods. We conducted a longitudinal, case–control study involving 42 CSU cases and 40 control cases comprising adults without associated conditions. Serial measurements were performed to assess the serum levels of IL-12p70, IL-12p35, and IL-12p40 at the onset of the disease (pre-therapy phase) and 6 weeks after the initiation of the treatment (post-therapy phase). Results. During the pre-therapeutic phase of CSU, elevated serum levels of IL-12 cytokine subtypes were detected compared to the control group. The relationship between IL-12 profiles and the course of CSU highlighted the pro-inflammatory role of IL-12p70 and the anti-inflammatory role of IL-12p35. Significant correlations were observed between IL-12p70 levels and the duration of the disease, as well as between IL-12 and the effectiveness of H1-antihistamines. Conclusions. The molecular background for the pleiotropic activities mediated by IL-12-derived cytokines in patients with CSU lies in the strict regulation of the production, signalling pathways, and cytokine-specific influences on the same pathophysiological events. The results of the present study suggest that the superficial layers of the skin serve as a cellular source of IL-12, a cytokine produced through antigenic stimulation. In patients with CSU, we identified independent, additive, or divergent functions of IL-12p70, IL-12p35, and IL-12p40, all relevant to systemic inflammation. These findings prove that the prototype programming of IL-12 is abnormal in CSU. Full article
Back to TopTop